The possible involvement of human parvovirus B19 infection in encephalopathy has been reported. To determine the characteristics of B19 viruses involved in such cases, we molecularly cloned a part of the B19 DNAs derived from the sera of three patients with encephalopathy (B19 strains N80, N81 and N82), following amplification by PCR. The nucleotide (nt) sequences of the cloned DNAs (nt 3147-3405) were then determined. The nucleotide sequence of N80 was similar to that of the known genome type of group II. The nucleotide sequences of N81 and N82 were similar to each other, but distinctly different from those of other B19 strains reported previously. Almost the entire genome of strain N81 (nt 229-4812) was molecularly cloned following amplification by PCR. Analyses of the restriction site polymorphisms of the cloned N81 DNAs showed that N81 is distantly related to other B 19 strains. Therefore, the two strains of N81 and N82 were defined as belonging to a new genome type, group V. Group V B19 virus has so far been isolated only from patients with encephalopathy.
Introduction
Human parvovirus B 19, originaliy discovered in the sera of apparently asymptomatic blood donors (Cossart et al., 1975) , is the aetiological agent of erythema infectiosum Nunoue et al., 1985 Nunoue et al., , 1987 . B19 virus particles contain a 5"6 kilobase (kb), linear, single-stranded DNA genome of either polarity, with terminal palindromic sequences 383 nucleotides (nt) in length (Clewley, 1984; Deiss et al., 1990; Shade et al., 1986; Summers et al., 1983) . As a conventional cell line for B19 virus replication in vitro has yet to be developed, it is difficult to propagate B19 in the laboratory. Therefore, amplification by PCR and molecular cloning of the B 19 genome have to be done to detect and analyse the B19 genome (Clewley, 1985; Cotmore & Tattersall, 1984; Umene & Nunoue, 1990 .
The genetic variability of viruses facilitates differentiation and classification of strains and examination of virus evolution, mode of transmission and distribution, and the association of strains of a particular genotype with biological characteristics and clinical manifestations. Morinet et al. (1986) were apparently the first to analyse genetic variation in B 19 virus strains. Mori et al. (1987) grouped B 19 strains into genome types (I, II, Ilia, * Author for correspondence. Fax +81 92 632 6402.
IIIb, IV and unassigned), and attempted to determine whether any one genome type could be correlated with a particular clinical manifestation of infection. They found no evidence of any correlation. We analysed genome types of B19 strains isolated in Japan at two different times, 1981 and 1986 to 1987 , and we noted a correlation between genome type and prevalence; genome types of B19 strains isolated during 1981 were similar to the group IV genome type, and those isolated during 1986 to 1987 were similar to group II (Umene & Nunoue, 1990) .
Infection with B19 can result in a wide spectrum of illness (Anderson, 1990; von Poblotzki et al., 1995) . Even prior to the discovery of B19 virus as the causative agent of erythema infectiosum, the association of encephalopathy with erythema infectiosum was reported (Balfour et al., 1970; Hall & Honer, 1977) . B19 DNA was identified in samples from subjects with encephalopathy (Watanabe et al., 1994) ; however, the characteristics of such B 19 DNAs remain to be elucidated. In the present work, we detected B 19 DNAs in the sera of three patients with encephalopathy and molecular cloning was done. B19 DNAs from two of these had similar genomic characteristics and were classed as a new group, named genome type V. B19 strains of the group V genome type derived only from patients with encephalopathy. We consider that one particular genome type may be related to clinical manifestations of infection. 
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Fig. 1. Nucleotide sequences of the region between nt 3141 and nt 3411 of B 19 virus strains, at the N terminus of the VP2 protein coding region. Nucleotide numbering was taken from Shade et al. (1986) . Nucleotide changes in comparison with strain Wi (group I genome type) are shown (Blundell et al., 1987; Mori et al., 1987) . Deduced amino acids are given in parentheses. Variations in amino acids in comparison with strain Wi are shown. A nucleotide change not resulting in a change in the encoded amino acid is indicated by (-) . Strain N 11 is representative of group II genome type, and strain N4 of group IV genome type (Umene & Nunoue, 1990) . Strains N80, N81 and N82 were isolated from sera of patients with encephalopathy, and were analysed in the present study. (Mori et al., 1987) , and almost the entire nucleotide sequence of Wi has been determined (Blundell et al., 1987) . B 19 virus strain N 11 is the representative of the group II genome type, and B19 virus strain N4 is the representative of the group IV genome type (Umene & Nunoue, 1990 , 1991 .
Methods

B19 viruses.
Extraction of BI9 DNA. Aliquots (20 gl) of sera from patients with encephalopathy assumed to be associated with B19 infection were incubated at 37 °C for 1 h in a mixture of proteinase K (0-1 mg/ml), 10 mM-Tris-HCl (pH 7.5), 1 mM-EDTA and 0.5 % SDS. The solution was extracted once with phenol, once with phenol-chloroform (1:1) and once with chloroform, followed by ethanol precipitation. The precipitate was dissolved in 10 gl of distilled water for PCR (Umene & Nunoue, 1993) .
PCR primers. Nucleotide (nt) numbering of B 19 genome DNA was taken from Shade et al. (1986) . Sense primer Prm 4-a (nt positions 3101-3120) and antisense primer Prm 4-b (nt positions 3445-3425) were used for detection of B 19 genome DNA and for molecular cloning to determine the nucleotide sequence between nt 3141 and 3411, at the N terminus of the VP2 protein coding region (Shade et al., 1986) . This region was assumed to contain an antigenic epitope (Fridell et al., 1989) . Three pairs of primers, sense primer PCR. DNA was amplified in 100 gl reaction mixtures containing 100 gM each of dATP, dCTP, dGTP and dTTP, 10 mM-Tri~HCI (pH 9.0), 2 mM-MgC12, 50 mM-KC1, 0.1% Triton X-100, 50 pmol each of the primer oligonucleotides, and sample DNA. After heating the mixture at 95 °C for 5 min, 2 units of Taq DNA polymerase (Promega) were added. The reaction mixture was overlaid with 50 gl of mineral oil; then 60 thermal cyclings were carried out in a DNA thermal cycler (Perkin-Elmer Cetus) to amplify an extremely small amount of DNA (Sevall, 1990) . Each cycle consisted of 1 rain at 94 °C, 2 min at 55 °C and 3 min at 72 °C. The PCR conditions were set to generate a sufficient amount of DNA product for detection and molecular cloning, not to optimize the fidelity.
Results
Detection of B19 DNA by PCR in the sera of patients with encephalopathy
Documented clinical cases of encephalopathy were assumed to be associated with B19 infection (Balfour et al., 1970; Hall & Honer, 1977; Watanabe et al., 1994) .
To search for B19 DNAs in such cases, we analysed sera from three patients with encephalopathy associated with a rash-like erythema infectiosum together with anti-B19 (2) 1 (0) 12 (2) 13 (3) 5 (2) 8 (0) 9 (1) 13 (2) 14 (3) 1 (1) Wi (I)* Nll (II)* N4 (IV)* NSOt N81t N82t * Strains Wi, N 11 and N4 are representative of each genome type of groups I, II and IV, respectively. # Strains N80, N81 and N82 were isolated from patients with encephalopathy.
IgM and IgG, thereby indicating the acute stage of B19 infection. We used Prm 4-a and Prm 4-b as a pair of PCR primers. DNA fragments 0.345 kilobase pairs (kb) in size (corresponding to nt 3101-3445), and expected to be amplified from the B19 genome using such a pair of primers, were detected in PCR products from all sera examined. B19 viruses present in the three samples were designated as strains N80, N81 and N82. B19 DNA was not detected in the cerebrospinal fluid.
Molecular cloning and DNA sequencing of PCR products
Genomic characteristics of B19 viruses isolated from patients with encephalopathy have apparently not been reported previously. The nucleotide sequence of a region of the B19 virus genome can be used to characterize genomic features of the virus (Umene & Nunoue, 1991 (Fig. 1) . The numbers of nucleotide substitutions in comparison with the consensus sequence of each DNA source were three (N82) or zero (N80 and N81), and were comparable to those in our previous study (Umene & Nunoue, 1993) . The consensus sequences of N80, N81 and N82 were compared with the corresponding sequences of the Mori et al. (1987) , and that of group V was done in the present study. Additional sites are marked on the maps, and lost sites are indicated in parentheses. Cutting sites of EcoRI, SalI and Xhol were not present in these B19 virus DNAs.
representative strain of each genome type, i.e. strains Wi (group I genome type), N11 (group II genome type) and N4 (group IV genome type) (Mori et al., 1987; Umene & Nunoue, 1990) (Fig. 1) . The nucleotide sequences of group IIIa and IIIb genome types originally defined by Mori et al. (1987) have not been reported, and thus could not be compared with those of other genome types. The numbers of nucleotide and amino acid sequence variations in the members of pairs of B19 strains were determined (Table 1 ). The nucleotide sequence of N80 was the same as that of N11 (group I1 genome type), except for one residue (Fig. 1, Table 1 ). Therefore, N80 was classified as group II genome type. The nucleotide sequences of strains N81 and N82 were the same except for one residue, and differed from those of four other B19 strains, Wi, Nll, N4 and N80 at eight or more residues (Table 1) . Because these two strains, N81 and N82, were similar to each other but distantly related to strains of other groups of genome type (I, II and IV), we proposed a new genome type, group V, to which strains N81 and N82 belong.
Molecular cloning of N81 genome DNAs, except the termini
To define the characteristics of the group V genome type, molecular cloning of almost all of the NS1 genome had to be done. An attempt to clone almost the entire N81 genome as a fragment of about 5 kb following PCR did not succeed. Parts of the N81 genome were amplified by PCR, using various pairs of primers, the objective being to search for a set of the fewest numbers of amplified fragments, overlapping each other and including almost the entire B19 genome. A set of three overlapping fragments of 2.4kb (nt209-2626, amplified using primers Prm 6-a and Prm 8-b), 1.2 kb (nt 2249-3477, amplified using primers Prm 8-a and Prm 10-b) and 1-8 kb (nt 3073-4833, amplified using primers Prm 10-a and Prm 6-b), spanning the region nt 229-4812 could be amplified to the extent that molecular cloning was feasible. The amplified products were molecularly cloned into the SmaI site of plasmid pUC18 after treatment with the Klenow fragment. We constructed four hybrid plasmids from each PCR product, as PCR products can contain errors in their sequences. Plasmids carrying the 2.4, 1-2 and 1-8 kb PCR products were named pUK372, pUK370 and pUK371, respectively. Mori et al. (1987) the B19 strains into groups I, II, IIIa, IIIb, IV and unassigned, on the basis of the distribution of RSPs (Fig.  2) . To elucidate the genomic characteristics of the group V genome type, we analysed RE cleavage profiles of hybrid plasmids carrying PCR products from strain N81 (i.e. pUK372, pUK370 and pUK371), using the set of thirteen 6-bp enzymes. Three new RSPs (the gain of a PstI site around nt 340, the gain of a HpaI site around nt 2390, and the gain ofa KpnI site around nt 4310) were detected on the cloned DNAs from N81 (Fig. 2) . To determine whether these three RSPs are present in N82, three regions of the N82 genome, including the site of each of the three RSPs, were amplified by PCR and digested with each RE. The three new RSPs were also detected in N82. These results reveal the similarity of N81 and N82, both of which are classified as group V genome type. The three new RSPs were not detected on genomes of groups of other genome types, and hence they can be used to distinguish strains of group V from those of other groups (Fig. 2) . Mori et al. (1987) classified 10 B19 strains as unassigned and strains with the same number of cleavage sites as N81 were not present in those classified as unassigned. Thus, B19 strains with the genomic characteristics seen in the group V genome type were identified for the first time in the present study.
Analyses of the restriction site polymorphism of the N81 genome using restriction endonucleases recognizing six base pair sequences
Characterization of the N81 genome using REs recognizing four or five base pair sequences
To better understand the genomic characteristics of the group V genome type, RE cleavage profiles of hybrid plasmids carrying DNA fragments derived from N81 (i.e. pUK372, pUK370 and pUK371) were analysed using a set of twelve REs recognizing 4-or 5-bp sequences (4-or 5-bp enzymes) -AluI, Cfrl3I, DdeI, HaeIII, HhaI, New B19 genome type in encephalopathy 2649 To determine the degree of genetic variation among the four genome types, differences in the number of variations listed in Table 3 were determined between each pair of genome types (Table 4 ). The degree of genetic variation was expressed as the variation index [(difference in the number of variations/total number of variations) x 100, rounded to the nearest whole number] (Table 4) (Umene & Nunoue, 1991) . The variation indexes between group V genome type and the other three groups were 59-74, and were larger than variation indexes between each pair of the three groups I, . Therefore, the group V genome type is the most distantly related to the other three groups. Mori et al. (1987) first formulated a classification of B19 virus strains, on the basis of analyses of RSP using a set of thirteen 6-bp enzymes. We previously characterized B19 strains isolated in Japan by analysing the viral genomic DNAs in three different ways (Umene & Nunoue, 1990 , t991, 1993 analyses of RSP using the set of thirteen 6-bp enzymes as done by Mori et al. (1987) , (ii) analyses of RSP using a set of twelve 4-or 5-bp enzymes, and (iii) partial nucleotide sequencing of the region between nt 3141 and nt 3411, corresponding to the N terminus of the VP2 protein coding region and assumed to contain an antigenic epitope (Fridell et al., 1989) . A large amount of DNA is required for RSP analysis. If a large quantity of B19 DNA is not available from clinical samples, molecular cloning of DNAs, including almost the entire B 19 genome, has to be done, because B19 cannot be propagated in conventional cell lines. Molecular cloning of a short region of B19 DNA after amplification by PCR is easier than molecular cloning of almost the entire B19 genome. Therefore, we determined partial nucleotide sequences of the region between nt 3141 and nt 3411 after molecular cloning of amplified products of B19 DNAs from patients with encephalopathy. Two B19 strains, NS1 and N82, from patients with encephalopathy were of a new genome type, group V (Fig. 1) . Variation indexes calculated based on the analyses of RSP using 4-or 5-bp enzymes facilitated a quantitative differentiation of the group V genome type from other groups ( Table 4 ). The establishment of this new genome type, group V, was supported by the three genome characterization methods (Fig. 2) .
Discussion
All nine B19 strains classified as group IIIa genome type by Mori et al. (1987) were isolated in the United Kingdom. B 19 strains classified as group IV genome type were isolated in Japan in 1981 (Umene & Nunoue, 1990) . B19 strains of group II were isolated in Japan during 1986 to 1987 and thereafter. B19 virus genome types seem to differ in their temporal and geographical distribution. In Europe and the United States, B19 strains of group II were isolated during 1984 to 1986 (Mori et al., 1987) . Therefore, B19 prevalence in Japan during 1986 to 1987 was assumed to be due to the entrance into Japan of B19 strains of group II. The only B19 strains of group V isolated so far are N81 and N82, and are restricted to Japan, as is group IV. The origins of B19 strains of group IV and V are unclear. Further analyses of the genomic characteristics of more BI9 strains isolated in different countries and at different times are required to define the epidemiology and evolution of the B19 virus.
Whether or not genome types of a virus are associated with biological properties and clinical manifestations requires further study. A genome type of hepatitis D virus was associated with the severe form of type D hepatitis that occurs in northern areas of South America (Casey et al., 1993) . Variants of Epstein-Barr virus (EBV) may be associated with the development and/or maintenance of nasopharyngeal carcinoma among the people of southern China (Chen et al., 1992; Jeng et al., 1994) . Morinet et al. (1986) first analysed the variation of B19 genomes using REs, and reserved speculation concerning a possible association of B19 variants with distinct clinical symptoms. Mori et al. (1987) found no correlation between one genome type and a particular clinical manifestation. We previously analysed the genomic characteristics of B19 strains isolated in Japan and noted a correlation between genome type and prevalence (Umene & Nunoue, 1990) . Genomic characteristics of B19 DNAs from damaged human fetuses (including hydrops fetalis) and from patients with leukaemia were analysed by partial nucleotide sequencing (Umene & Nunoue, 1993) ; they proved to be similar to those of common genome types of group II or IV. Thus, clinical manifestations did not correlate with particular genome types. In the present study, we analysed the genomic characteristics of three B19 strains from sera of patients with encephalopathy. One (NS0) was of group II genome type, and two (N81 and N82) were of a new genome type, group V. Of the genome types so far analysed, the group V genome type was the most distantly related to the others (Table 4) . B19 strains of group V genome type may thus have biological properties distinct from those of other genome types, possibly correlating with a particular clinical manifestation. Three genome types of B19 strains (groups II, IV and V) were isolated in Japan from 1981 to 1991 (Umene & Nunoue, 1990 , 1991 . While B19 strains of group II and IV genome types were isolated from patients with a variety of clinical manifestations, B19 strains of group V genome type were isolated only from patients with encephalopathy. One B 19 virus of group II genome type (NS0) was isolated from the serum of a patient with encephalopathy, and hence B19 virus associated with encephalopathy is not restricted to a particular genome type. Genomic characterization of larger numbers of B19 strains, including those derived from patients with encephalopathy will be needed in order to address the question of whether or not group V genome type is more frequently associated with encephalopathy than are other genome types.
